DEPAKOTE CP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEPAKOTE CP (DEPAKOTE CP).
Valproate increases GABA concentration in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase. It also blocks voltage-gated sodium channels and T-type calcium channels.
| Metabolism | Extensively metabolized in the liver via glucuronidation (30-50%), mitochondrial beta-oxidation (40%), and CYP450 (including CYP2C9, CYP2A6) to various metabolites. |
| Excretion | Renal: 30-50% as glucuronide conjugates, 3% as unchanged drug; fecal: minimal; less than 3% excreted in bile. |
| Half-life | Terminal elimination half-life is 9-16 hours (mean ~12 hours) in adults; prolonged in hepatic impairment, elderly, and neonates. |
| Protein binding | 86-90% bound to albumin; decreased binding in renal failure, hypoalbuminemia, and at higher concentrations. |
| Volume of Distribution | 0.12-0.17 L/kg; low Vd consistent with limited extravascular distribution and high protein binding. |
| Bioavailability | Oral (immediate-release): ~92%; oral (sustained-release): about 10-20% lower peak but similar overall absorption; IV: 100%. |
| Onset of Action | Oral: 3-4 days to reach steady state; clinical antiepileptic effect may require 1-2 weeks. IV: within minutes for seizure termination. |
| Duration of Action | Oral: dosing every 12 hours maintains therapeutic levels; sustained-release forms allow once-daily dosing. Clinical effect duration parallels drug presence in CNS. |
250-500 mg orally twice daily, titrated by 250 mg/day every 3-7 days; maximum 60 mg/kg/day. Target trough serum concentration: 50-100 mcg/mL.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | No specific dose adjustments for renal impairment. Caution in significant renal disease. Avoid in severe renal failure (CrCl <10 mL/min) due to risk of valproate toxicity. |
| Liver impairment | Contraindicated in patients with significant hepatic impairment, acute liver disease, or Child-Pugh class C. For mild-moderate impairment (Child-Pugh A/B), reduce dose and monitor liver function closely; no specific dose reduction established. |
| Pediatric use | Weight-based: Initial 10-15 mg/kg/day divided twice daily, titrate by 5-10 mg/kg/day weekly up to 60 mg/kg/day; maximum 60 mg/kg/day. For children <10 kg, use syrup formulation. |
| Geriatric use | Start at lower doses (250 mg twice daily), titrate slowly. Monitor for sedation, tremor, thrombocytopenia, and drug interactions. Reduce dose if clearance decreases. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DEPAKOTE CP (DEPAKOTE CP).
| Breastfeeding | Excreted in breast milk with M/P ratio 0.1-0.5. Relative infant dose 2-10% of maternal weight-adjusted dose. Monitor infant for drowsiness, poor feeding, thrombocytopenia, hepatotoxicity. Consider risk/benefit; mainly compatible if maternal levels therapeutic and infant monitored. |
| Teratogenic Risk | Highest risk in first trimester: neural tube defects (spina bifida, anencephaly) with 3-5% absolute risk, cardiac defects, hypospadias, cleft palate, craniofacial anomalies. Second/third trimester: fetal growth restriction, neonatal hyperglycemia, hypoglycemia, withdrawal syndrome, coagulopathy, hyperbilirubinemia, hepatotoxicity. Long-term neurodevelopmental delays (IQ reduction) irrespective of trimester. |
■ FDA Black Box Warning
Hepatotoxicity: Fatal hepatic failure has occurred, especially in children under 2 years and patients with mitochondrial disorders. Pancreatitis: Fatal hemorrhagic pancreatitis has been reported.
| Common Effects | Decreased body temperature Dizziness Sleepiness Tremors Paresthesia tingling or pricking sensation Anemia low number of red blood cells Decreased sodium level in blood Liver injury Gastrointestinal disturbance Hypersensitivity Deafness Urinary incontinence Increase in body weight Pain during periods |
| Serious Effects |
Hypersensitivity to valproate, hepatic disease or significant hepatic dysfunction, known mitochondrial disorders (especially POLG mutations), urea cycle disorders, pregnancy (for migraine prophylaxis).
| Precautions | Hepatotoxicity (risk factors: young age, polytherapy, metabolic disorders), pancreatitis, teratogenicity (neural tube defects), thrombocytopenia, hyperammonemia, hypothermia, multi-organ hypersensitivity reaction. |
Loading safety data…
| Fetal Monitoring | Pre-conception: high-dose folic acid (4-5 mg/day), baseline LFTs, CBC, valproate level. During pregnancy: serial maternal valproate levels (goal 50-100 mcg/mL), LFTs, CBC every trimester. Fetal: high-resolution ultrasound with fetal echocardiography at 18-20 weeks; AFP screening for NTDs. Neonatal: monitor for bleeding, glucose, bilirubin, liver function. |
| Fertility Effects | Women: menstrual irregularities, ovulatory dysfunction, polycystic ovary-like syndrome (PCOS-like) with hyperandrogenism, elevated LH/FSH ratio, impaired fertility. Men: reduced sperm count, motility, abnormal morphology; reversible upon discontinuation. |